Introduction: Cancer is a devastating disease; however, several therapeutic advances have
recently been made, wherein EGFR and its family members have emerged as useful
biomarkers and therapeutic targets. EGFR, a transmembrane glycoprotein is a member of
the ERBB receptor tyrosine kinase superfamily. EGFR binds to its cognate ligand EGF,
which further induces tyrosine phosphorylation and receptor dimerization with other family
members leading to enhanced uncontrolled proliferation. Several anti-EGFR therapies such …

Introduction Epidermal growth factor receptor (EGFR) is frequently amplified, overexpressed,
and mutated in multiple cancers. In normal cell physiology, EGFR signaling controls cellular
differentiation, proliferation, growth, and survival. During tumorigenesis, mutations in EGFR
lead to increased kinase activity supporting survival, uncontrolled proliferation, and
migratory functions of cancer cells. Molecular agents targeting the EGFR pathway have
been discovered, and their efficacy has been demonstrated in clinical trials. To date, 14 …